Novel Therapeutic Targets in Liver Fibrosis

Zhang, Jinhang; Liu, Qinhui; He, Jinhan; Li, Yanping

doi:10.3389/fmolb.2021.766855

Cited by 26 publications

(26 citation statements)

References 210 publications

(217 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diminishing the life-threatening complications of liver fibrosis can be a critical therapeutically target, even if the fibrotic process is advanced. Therefore, therapeutic interventions are studied to decrease oxidative stress and inflammation and prevent hepatic fibrosis [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Protective Effect of Liposomal Epigallocatechin-Gallate in Experimental Gentamicin-Induced Hepatotoxicity

et al. 2022

View full text Add to dashboard Cite

Our study aimed to assess the effect of liposomal epigallocatechin-gallate (LEGCG) compared with epigallocatechin-gallate (EGCG) solution on hepatic toxicity induced by gentamicin (G) administration in rats. Five groups were evaluated, a control group (no G administration) and four groups that received G (1 mL, i.p, 80 mg/kg b.w. (body weight/day), for 7 days) to which we associated daily administration 30 min before G of EGCG (G-EGCG, 2.5 mg/0.1 kg b.w.), LEGCG (G-LEGCG, 2.5 mg/0.1 kg b.w.) or silymarin (100 mg/kg b.w./day). The nitro-oxidative stress (NOx), catalase (CAT), TNF-α, transaminases, creatinine, urea, metalloproteinase (MMP) 2 and 9, and liver histopathological changes were evaluated. LEGCG exhibited better efficacy than EGCG, improving the oxidant/antioxidant balance (p = 0.0125 for NOx and 0.0032 for CAT), TNF-α (p < 0.0001), MMP-2 (p < 0.0001), aminotransferases (p = 0.0001 for AST and 0.0136 for ALT), creatinine (p < 0.0001), urea (p = 0.0006) and histopathologic liver changes induced by gentamicin. Our study demonstrated the beneficial effect of EGCG with superior results of the liposomal formulation for hepatoprotection in experimental hepatic toxicity induced by gentamicin.

show abstract

Section: Introductionmentioning

confidence: 99%

Protective Effect of Liposomal Epigallocatechin-Gallate in Experimental Gentamicin-Induced Hepatotoxicity

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Cirrhosis, which is frequently linked with liver failure, portal hypertension, and HCC [ 119 ], is the end outcome of chronic fibrosis. Generally, dysfunctional hepatic stellate cells (HSCs) play a significant role in liver fibrogenesis [ 120 ]. Under normal physiological settings, HSCs operate as vitamin A stores in their inactive form.…”

Section: Resultsmentioning

confidence: 99%

Hepatoprotective Effect of Kaempferol: A Review of the Dietary Sources, Bioavailability, Mechanisms of Action, and Safety

Alkandahri

Pamungkas

Oktoba

et al. 2023

Advances in Pharmacological and Pharmaceutical Sciences

View full text Add to dashboard Cite

The liver is the body’s most critical organ that performs vital functions. Hepatic disorders can affect the physiological and biochemical functions of the body. Hepatic disorder is a condition that describes the damage to cells, tissues, structures, and functions of the liver, which can cause fibrosis and ultimately result in cirrhosis. These diseases include hepatitis, ALD, NAFLD, liver fibrosis, liver cirrhosis, hepatic failure, and HCC. Hepatic diseases are caused by cell membrane rupture, immune response, altered drug metabolism, accumulation of reactive oxygen species, lipid peroxidation, and cell death. Despite the breakthrough in modern medicine, there is no drug that is effective in stimulating the liver function, offering complete protection, and aiding liver cell regeneration. Furthermore, some drugs can create adverse side effects, and natural medicines are carefully selected as new therapeutic strategies for managing liver disease. Kaempferol is a polyphenol contained in many vegetables, fruits, and herbal remedies. We use it to manage various diseases such as diabetes, cardiovascular disorders, and cancers. Kaempferol is a potent antioxidant and has anti-inflammatory effects, which therefore possesses hepatoprotective properties. The previous research has studied the hepatoprotective effect of kaempferol in various hepatotoxicity protocols, including acetaminophen (APAP)-induced hepatotoxicity, ALD, NAFLD, CCl4, HCC, and lipopolysaccharide (LPS)-induced acute liver injury. Therefore, this report aims to provide a recent brief overview of the literature concerning the hepatoprotective effect of kaempferol and its possible molecular mechanism of action. It also provides the most recent literature on kaempferol’s chemical structure, natural source, bioavailability, and safety.

show abstract

“…Translational research on antifibrotic therapy has focused on targeting fibrosis and fibrolysis pathways [ 150 ]. Among the inhibitors of HSC activation (e.g., blockers of cannabinoid receptor 1 angiotensin-converting enzyme, angiotensin receptor, endothelin 1 receptor), the farnesoid X receptor (FXR) antagonist, obeticholic acid (OCA), has shown the greatest promise.…”

Section: Therapymentioning

confidence: 99%

Liver fibrosis in children: a comprehensive review of mechanisms, diagnosis, and therapy

Özdoğan

Arıkan

2023

Clin Exp Pediatr

View full text Add to dashboard Cite

Chronic liver disease incidence is increasing among children worldwide due to a multitude of epidemiological changes. Most of these chronic insults to the pediatric liver progress to fibrosis and cirrhosis to different degrees. Liver and immune physiology differs significantly in children from adults. Because most of pediatric liver diseases have no definitive therapy, a better understanding of population and disease-specific fibrogenesis is mandatory. Furthermore, fibrosis development has prognostic significance and often guide treatment. Evaluation of liver fibrosis continues to rely on the gold-standard liver biopsy. However, many high-quality studies put forward the high diagnostic accuracy of numerous diagnostic modalities in this setting. Herein, we summarize and discuss the recent literature on fibrogenesis with an emphasis on pediatric physiology along with a detailed outline of disease-specific signatures, noninvasive diagnostic modalities, and the potential for antifibrotic therapies.

show abstract

Novel Therapeutic Targets in Liver Fibrosis

Cited by 26 publications

References 210 publications

Protective Effect of Liposomal Epigallocatechin-Gallate in Experimental Gentamicin-Induced Hepatotoxicity

Protective Effect of Liposomal Epigallocatechin-Gallate in Experimental Gentamicin-Induced Hepatotoxicity

Hepatoprotective Effect of Kaempferol: A Review of the Dietary Sources, Bioavailability, Mechanisms of Action, and Safety

Liver fibrosis in children: a comprehensive review of mechanisms, diagnosis, and therapy

Contact Info

Product

Resources

About